Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,otherLiab,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,netBorrowings,effectOfExchangeRate,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,INM,9328722.0,8050710,1772593,,-3101475,,-3101475,1333725,0,-3133739,-3133739,,,,,,0,0,3133739,0,32264,,-3101475,-3101475,1085748.0,21292201.0,1930529.0,10414470.0,12344999.0,60587417.0,45724.0,-71593717.0,128569.0,14655.0,9454113.0,1714295.0,128569.0,347892.0,10896704.0,41.0,70300.0,795343.0,,-532863.0,4044865.0,-1298062.0,4462500.0,-566740.0,-4611605.0,49748.0,84546.0,-417635.0,186501.0,,,,,9182409.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,0.31999993,0.15841581,2.02 - 8.94,-6.5999994,-0.738255,2.02,8.94,1593993600,1620909000,1620909000,1620909000,5.8823476,2.29 - 2.3899,2.21,0.0,0.0,8,8,finmb_9199217,NasdaqCM,InMed Pharmaceuticals Inc.,CAD,71615,92871,2.4685714,-0.12857151,-0.052083366,3.1965652,-0.85656524,-0.26796427,18838660,15,America/New_York,EDT,-14400000,4,NCM,PRE,us_market,InMed Pharmaceuticals Inc.,2.34,1630526402,0.12999988,2.34,2.3899,2.29,44260,1.43,,,8.94,2.02,2.4686,3.1966,71.61k,92.87k,8.05M,,8M,0.86%,6.34%,93.35k,1,,1.04%,13.71k,,,,,,0.00%,"Jul 05, 2020",,1:33,"Jul 05, 2020","Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-52.16%,-105.12%,,,,,-8.56M,-9.05M,,,9.45M,1.17,295.05k,2.83,6.36,,-9.57M,-5.77M,Value,V6C 1B4,Healthcare,"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",Vancouver,604 669 7207,BC,1640908800,Canada,http://www.inmedpharma.com,86400,815 West Hastings Street,778 945 6800,Biotechnology,Suite 310
t-1,INM,6481278.0,8050710,937948,,-2243782,,-2243782,959554,0,-1934318,-1934318,,-360350.0,,,,0,0,1934318,0,-309464,,-2243782,-2243782,1109535.0,17946374.0,4156609.0,7590813.0,11747422.0,58008112.0,45162.0,-68492242.0,128569.0,14655.0,10020853.0,2153637.0,128569.0,373844.0,10249388.0,63.0,154846.0,930393.0,1763980.0,128949.0,6977601.0,138582.0,8010000.0,5716545.0,-1756016.0,61196.0,-96922.0,-1049382.0,175122.0,16982.0,494960.0,,,8095751.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,0.31999993,0.15841581,2.02 - 8.94,-6.5999994,-0.738255,2.02,8.94,1593993600,1620909000,1620909000,1620909000,5.8823476,2.29 - 2.3899,2.21,0.0,0.0,8,8,finmb_9199217,NasdaqCM,InMed Pharmaceuticals Inc.,CAD,71615,92871,2.4685714,-0.12857151,-0.052083366,3.1965652,-0.85656524,-0.26796427,18838660,15,America/New_York,EDT,-14400000,4,NCM,PRE,us_market,InMed Pharmaceuticals Inc.,2.34,1630526402,0.12999988,2.34,2.3899,2.29,44260,1.43,,,8.94,2.02,2.4686,3.1966,71.61k,92.87k,8.05M,,8M,0.86%,6.34%,93.35k,1,,1.04%,13.71k,,,,,,0.00%,"Jul 05, 2020",,1:33,"Jul 05, 2020","Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-52.16%,-105.12%,,,,,-8.56M,-9.05M,,,9.45M,1.17,295.05k,2.83,6.36,,-9.57M,-5.77M,Value,V6C 1B4,Healthcare,"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",Vancouver,604 669 7207,BC,1640908800,Canada,http://www.inmedpharma.com,86400,815 West Hastings Street,778 945 6800,Biotechnology,Suite 310
t-2,INM,4542484.0,8050710,1163721,,-2140553,,-2140553,740929,0,-2094555,-2094555,,-360350.0,,,,0,0,2094555,0,-45998,,-2140553,-2140553,1068981.0,15599115.0,2814033.0,5611465.0,8425498.0,68579890.0,57500.0,-78567540.0,,18659.0,5998943.0,2499769.0,,512923.0,6824935.0,74.0,69193.0,2404526.0,,214094.0,-107756.0,-60674.0,8010000.0,-1913213.0,-1805457.0,59607.0,-7399.0,-86117.0,129468.0,-21639.0,494960.0,,,4325166.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,0.31999993,0.15841581,2.02 - 8.94,-6.5999994,-0.738255,2.02,8.94,1593993600,1620909000,1620909000,1620909000,5.8823476,2.29 - 2.3899,2.21,0.0,0.0,8,8,finmb_9199217,NasdaqCM,InMed Pharmaceuticals Inc.,CAD,71615,92871,2.4685714,-0.12857151,-0.052083366,3.1965652,-0.85656524,-0.26796427,18838660,15,America/New_York,EDT,-14400000,4,NCM,PRE,us_market,InMed Pharmaceuticals Inc.,2.34,1630526402,0.12999988,2.34,2.3899,2.29,44260,1.43,,,8.94,2.02,2.4686,3.1966,71.61k,92.87k,8.05M,,8M,0.86%,6.34%,93.35k,1,,1.04%,13.71k,,,,,,0.00%,"Jul 05, 2020",,1:33,"Jul 05, 2020","Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-52.16%,-105.12%,,,,,-8.56M,-9.05M,,,9.45M,1.17,295.05k,2.83,6.36,,-9.57M,-5.77M,Value,V6C 1B4,Healthcare,"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",Vancouver,604 669 7207,BC,1640908800,Canada,http://www.inmedpharma.com,86400,815 West Hastings Street,778 945 6800,Biotechnology,Suite 310
t-3,INM,6530078.0,8050710,1255617,,-2312613,,-2312613,598258,0,-2209340,-2209340,,-25426.0,,,,0,0,2209340,0,-103273,,-2312613,-2312613,1091642.0,15468817.0,2622407.0,7621720.0,10244127.0,68579890.0,453650.0,-76426987.0,,,7912156.0,2284418.0,,549869.0,8602616.0,261.0,61794.0,2190432.0,,330821.0,-73051.0,-267210.0,8010000.0,-1974239.0,-1901810.0,59538.0,-16269.0,-40593.0,303923.0,-32458.0,494960.0,622.0,622.0,6318198.0,en-US,US,EQUITY,True,Delayed Quote,USD,False,False,0,0.31999993,0.15841581,2.02 - 8.94,-6.5999994,-0.738255,2.02,8.94,1593993600,1620909000,1620909000,1620909000,5.8823476,2.29 - 2.3899,2.21,0.0,0.0,8,8,finmb_9199217,NasdaqCM,InMed Pharmaceuticals Inc.,CAD,71615,92871,2.4685714,-0.12857151,-0.052083366,3.1965652,-0.85656524,-0.26796427,18838660,15,America/New_York,EDT,-14400000,4,NCM,PRE,us_market,InMed Pharmaceuticals Inc.,2.34,1630526402,0.12999988,2.34,2.3899,2.29,44260,1.43,,,8.94,2.02,2.4686,3.1966,71.61k,92.87k,8.05M,,8M,0.86%,6.34%,93.35k,1,,1.04%,13.71k,,,,,,0.00%,"Jul 05, 2020",,1:33,"Jul 05, 2020","Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-52.16%,-105.12%,,,,,-8.56M,-9.05M,,,9.45M,1.17,295.05k,2.83,6.36,,-9.57M,-5.77M,Value,V6C 1B4,Healthcare,"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",Vancouver,604 669 7207,BC,1640908800,Canada,http://www.inmedpharma.com,86400,815 West Hastings Street,778 945 6800,Biotechnology,Suite 310
